Literature DB >> 11940052

Indirect evidence for decreased hypothalamic somatostatinergic tone in anorexia nervosa.

R K Støving1, M Andersen, A Flyvbjerg, J Frystyk, J Hangaard, J Vinten, O G Koldkjaer, C Hagen.   

Abstract

OBJECTIVE: In animals, somatostatin (SRIH) and growth hormone (GH)-releasing hormone (GHRH) increase feeding via a common neural mechanism. Furthermore, SRIH counteracts the suppressive action of corticotrophin-releasing hormone (CRH) on food intake. Hypothetically, SRIH could be involved in the central feeding mechanism in anorexia nervosa (AN). Peripheral administration of pyridostigmine (PD) minimizes the release of hypothalamic SRIH.
DESIGN: To study the influence of hypothalamic somatostatinergic inhibition on the exaggerated somatotroph responsiveness to GHRH in patients with severe AN, two GHRH stimulation tests were performed in random order following pretreatment with placebo or PD 2 mg/kg body weight in 13 patients and in 10 age-matched healthy controls. The test procedure was repeated in the patients after weight gain.
RESULTS: In controls, PD potentiated the GHRH-stimulated GH rise but this effect was absent in AN patients. The relative potentiating effect of PD was inversely correlated to cortisol excretion levels and positively correlated to leptin serum levels. After weight gain the relative PD effect increased twofold.
CONCLUSION: The pyridostigmine-GHRH responsive pattern points indirectly to greater SRIH withdrawal and greater GHRH release in anorexia nervosa. Moreover, hypothalamic SRIH activity seems to be inversely related to cortisol levels, indirectly supporting the hypothesis that SRIH and CRH neuronal activity are inversely related in anorexia nervosa. Leptin, which is believed to act on hypothalamic feeding mechanisms, seems to be positively related to SRIH activity. Finally, the present data demonstrate that the potentiating effect of pyridostigmine in anorexia nervosa is related to body mass index and increases upon weight gain, suggesting that the low somatostatinergic tone is not primary but is related to the weight loss.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11940052     DOI: 10.1046/j.1365-2265.2002.01485.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Development of acromegaly in a patient with anorexia nervosa: pathogenetic and diagnostic implications.

Authors:  E de Menis; M Gola; A Giustina
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice.

Authors:  José Córdoba-Chacón; Manuel D Gahete; Justo P Castaño; Rhonda D Kineman; Raul M Luque
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-13       Impact factor: 4.310

Review 3.  The Dynamics of Neurosteroids and Sex-Related Hormones in the Pathogenesis of Alzheimer's Disease.

Authors:  Milad Hasanpour; Alireza Nourazarian; Mohammad Hossein Geranmayeh; Masoud Nikanfar; Fatemeh Khaki-Khatibi; Reza Rahbarghazi
Journal:  Neuromolecular Med       Date:  2018-05-04       Impact factor: 3.843

Review 4.  Neuroendocrine consequences of anorexia nervosa in adolescents.

Authors:  Madhusmita Misra; Anne Klibanski
Journal:  Endocr Dev       Date:  2009-11-24

Review 5.  MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical update.

Authors:  René Klinkby Støving
Journal:  Eur J Endocrinol       Date:  2019-01-01       Impact factor: 6.664

Review 6.  The role of "mixed" orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa.

Authors:  Kvido Smitka; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer; Jara Nedvidkova
Journal:  Int J Endocrinol       Date:  2013-09-09       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.